- Home
- MSN vs MYNZ Comparison
MSN vs MYNZ Comparison
Compare MSN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSN
- MYNZ
- Stock Information
- Founded
- MSN 1948
- MYNZ 2021
- Country
- MSN United States
- MYNZ Germany
- Employees
- MSN N/A
- MYNZ N/A
- Industry
- MSN Consumer Electronics/Appliances
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- MSN Consumer Staples
- MYNZ Health Care
- Exchange
- MSN Nasdaq
- MYNZ Nasdaq
- Market Cap
- MSN 8.6M
- MYNZ 7.0M
- IPO Year
- MSN 1994
- MYNZ 2021
- Fundamental
- Price
- MSN $0.40
- MYNZ $1.39
- Analyst Decision
- MSN
- MYNZ Buy
- Analyst Count
- MSN 0
- MYNZ 2
- Target Price
- MSN N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- MSN 16.2K
- MYNZ 72.2K
- Earning Date
- MSN 08-13-2025
- MYNZ 07-01-2025
- Dividend Yield
- MSN N/A
- MYNZ N/A
- EPS Growth
- MSN N/A
- MYNZ N/A
- EPS
- MSN N/A
- MYNZ N/A
- Revenue
- MSN $11,140,000.00
- MYNZ $893,991.00
- Revenue This Year
- MSN N/A
- MYNZ $26.06
- Revenue Next Year
- MSN N/A
- MYNZ $4.97
- P/E Ratio
- MSN N/A
- MYNZ N/A
- Revenue Growth
- MSN 27.46
- MYNZ N/A
- 52 Week Low
- MSN $0.35
- MYNZ $1.38
- 52 Week High
- MSN $0.83
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- MSN 45.72
- MYNZ 21.48
- Support Level
- MSN $0.41
- MYNZ $1.95
- Resistance Level
- MSN $0.45
- MYNZ $2.15
- Average True Range (ATR)
- MSN 0.03
- MYNZ 0.14
- MACD
- MSN -0.00
- MYNZ -0.03
- Stochastic Oscillator
- MSN 25.00
- MYNZ 1.95
About MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. Its products are offered to encompass televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products. geographically, it derives a majority of its revenue from the United States.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.